SUZ12通过调控肝癌细胞及人脐静脉内皮细胞的血管生成发挥抑癌作用

doi:10.20223/j.cnki.1000-8535.2025.01.010

广州医药 ›› 2025, Vol. 56 ›› Issue (1): 71-76.DOI: 10.20223/j.cnki.1000-8535.2025.01.010

SUZ12通过调控肝癌细胞及人脐静脉内皮细胞的血管生成发挥抑癌作用

何淦清¹, 舒鑫妮², 胡晖², 侯明君², 曾观海², 魏达强², 王坤元¹, 杨辉¹, 聂玉强³

1 广州医科大学附属第二医院消化内科（广东广州 510260）
2 广州医科大学第二临床学院（广东广州 511495）
3 华南理工大学附属第二医院（广州市第一人民医院）消化内科（广东广州 510180）

收稿日期:2024-04-11 出版日期:2025-01-20 发布日期:2025-02-13
通讯作者: 王坤元,E-mail：kalawang@foxmail.com
基金资助:
国家自然科学基金青年科学基金（82102813）; 2019年度广州医科大学大学生实验室开放项目（201910570008）; 广东省基础与应用基础研究基金项目（2021A1515010795,2020A1515011255）; 广东省医学科研基金（A2021157）

Anti-cancer role of SUZ12 by regulating angiogenesis of liver cancer cells and human umbilical vein endothelial cells

HE Ganqing¹, SHU Xinni², HU Hui², Hou Mingjun², ZENG Guanhai², WEI Daqiang², WANG Kunyuan¹, YANG Hui¹, NIE Yuqiang³

1 Department of Gastroenterology,the Second Affiliated Hospital of Guangzhou Medical University,Guangzhou 510260,China
2 The Second Clinical School,Guangzhou Medical University,Guangzhou 511495,China
3 Department of Gastroenterology,the Second Affiliated Hospital of South China University of Technology,Guangzhou First People's Hospital,Guangzhou 510180,China

Received:2024-04-11 Online:2025-01-20 Published:2025-02-13

摘要/Abstract

摘要： 目的探讨多梳蛋白SUZ12对肝细胞肝癌（HCC）细胞增殖、血管生成拟态形成和人脐静脉内皮细胞（HUVECs）血管生成的影响。方法分别利用MTT比色法及体外血管生成实验检测SUZ12表达水平改变对HCC细胞SMMC-7721、Hep3B增殖、血管生成拟态形成和HUVECs血管生成的影响。结果 MTT结果显示,在HCC细胞中分别敲低或过表达SUZ12均对HCC细胞的增殖能力无明显影响。将SUZ12低表达HCC细胞与HUVECs共培养后,HCC细胞的血管生成拟态管样结构形成增多。此外,将SUZ12敲低组HCC细胞的培养上清用于培养HUVECs后,HUVECs的血管生成拟态管样结构形成也明显增多。结论 SUZ12对HCC细胞的增殖无影响,其在HCC中可抑制HCC细胞和HUVECs的血管生成拟态管样结构形成。上述结果提示SUZ12可能通过调控HCC细胞及HUVECs的血管生成发挥抑癌作用。

关键词: 多梳蛋白SUZ12, 肝细胞肝癌, 人脐静脉内皮细胞, 血管生成

Abstract: Objective To investigate the effects of SUZ12 on cell proliferation of hepatocellular carcinoma（HCC）,vasculogenic mimicry formation and human umbilical vein endothelial cells（HUVECs）angiogenesis．Methods MTT assay was performed to detect the proliferation of SMMC-7721 and Hep3B cells．The effects of SUZ12 on the angiogenesis of HCC cells and HUVECs cells were studied by in vitro angiogenesis experiment．Results The result of MTT assay showed that SUZ12 knockdown or overexpression in HCC cells had no significant effect on the proliferation of HCC cells．We found that when HCC cells with low SUZ12 expression were co-cultured with HUVECs cells,the formation of vasculogenic mimicry tubular structures in HCC cells increased．In addition,we also found that after the culture supernatant of HCC cells in the SUZ12 knockdown group was used to culture HUVECs cells,the formation of vasculogenic mimicry tubular structures in HUVECs cells also increased significantly．Conclusions SUZ12 has no effect on the proliferation of HCC cells,but it can inhibit the formation of vasculogenic mimicry tubular structures in HCC cells and HUVECs cells．These results suggest that SUZ12 plays a role in cancer inhibition by regulating the angiogenesis of HCC cells and HUVECs cells．

Key words: SUZ12, hepatocellular carcinoma, human umbilical vein endothelial cells, angiogenesis

何淦清, 舒鑫妮, 胡晖, 侯明君, 曾观海, 魏达强, 王坤元, 杨辉, 聂玉强. SUZ12通过调控肝癌细胞及人脐静脉内皮细胞的血管生成发挥抑癌作用[J]. 广州医药, 2025, 56(1): 71-76.

HE Ganqing, SHU Xinni, HU Hui, Hou Mingjun, ZENG Guanhai, WEI Daqiang, WANG Kunyuan, YANG Hui, NIE Yuqiang. Anti-cancer role of SUZ12 by regulating angiogenesis of liver cancer cells and human umbilical vein endothelial cells[J]. Guangzhou Medical Journal, 2025, 56(1): 71-76.

参考文献

[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] 郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.
[3] SHI J F,CAO M,WANG Y,et al.Is it possible to halve the incidence of liver cancer in China by 2050?[J] Int J Cancer 2021,148(5),1051-1065.
[4] LLOVET J M,de BAERE T,KULIK L,et al.Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma[J].Nat Rev Gastroenterol Hepatol 2021,18(5),293-313.
[5] ANWANWAN D,SINGH S K,SINGH S,et al.Challenges in liver cancer and possible treatment approaches[J].Biochim Biophys Acta Rev Cancer 2020,1873(1),188314.
[6] YANG J D,HAINAUT P,GORES G J,et al.A global view of hepatocellular carcinoma:trends,risk,prevention and management[J].Nat Rev Gastroenterol Hepatol,2019,16(10):589-604.
[7] LEVRERO M,ZUCMAN-ROSSI J.Mechanisms of HBV-induced hepatocellular carcinoma[J].J HEPATOL,2016,64(1 Suppl):S84-S101.
[8] STUDACH LL,MENNE S,CAIRO S,et al.Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein[J].Hepatology,2012,56(4):1240-1251.
[9] XUE C,WANG K,JIANG X,et al.The down-regulation of SUZ12 accelerates the migration and invasion of liver cancer cells via activating ERK1/2 pathway[J].J Cancer,2019,10(6):1375-1384.
[10] HANAHAN D,WEINBERG R A.Hallmarks of cancer:the next generation[J].Cell,2011,144(5):646-674.
[11] FANG J H,XU L,SHANG L R,et al.Vessels That Encapsulate Tumor Clusters(VETC)pattern is a predictor of sorafenib benefit in patients with hepatocellular carcinoma[J].Hepatology,2019,70(3):824-839.
[12] HANAHAN D,FOLKMAN J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J].Cell,1996,86(3):353-364.
[13] ORLANDI P,SOLINI A,BANCHI M,et al.Antiangiogenic drugs in NASH:Evidence of a possible new therapeutic approach[J].Pharmaceuticals(Basel).2021,14(10):995.
[14] MORSE M A,SUN W,KIM R,et al.The role of angiogenesis in hepatocellular carcinoma[J].Cancer Res,2019,25(3):912-920.
[15] WU Y,HU H,ZHANG W,et al.SUZ12 is a novel putative oncogene promoting tumorigenesis in head and neck squamous cell carcinoma[J].J Cell Mol Med,2018,22(7):3582-3594.
[16] LIU C,SHI X,WANG L,et al.SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis[J].Tumour Biol,2014,35(6):6073-6082.
[17] XIA R,JIN FY,LU K,et al.SUZ12 promotes gastric cancer cell proliferation and metastasis by regulatingKLF2 and E-cadherin[J].Tumour Biol,2015,36(7):5341-5351.
[18] LEE W,TECKIE S,WIESNER T,et al.PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors[J].Nat Genet,2014,46(11):1227-1232.
[19] WANG W H,STUDACH L L,ANDRISANI O M.Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus(HBV)X protein-mediated hepatocyte transformation and in HBV replication[J].Hepatology,2011,53(4):1137-1147.
[20] FANG J H,ZHOU H C,ZHANG C,et al.A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner[J].Hepatology,2015,62(2):452-465.
[21] LI M,YAN T,CAI Y,et al.Expression of matrix metalloproteinases and their association with clinical characteristics of solid tumors[J].Gene,2023(850):146927.
[22] RENNE S L,WOO H Y,ALLEGRA S,et al.Vessels pattern is a predictor of sorafenib benefit in patients with hepatocellular carcinoma[J].Hepatology,2020 ,71(1):183-195.

SUZ12通过调控肝癌细胞及人脐静脉内皮细胞的血管生成发挥抑癌作用

Anti-cancer role of SUZ12 by regulating angiogenesis of liver cancer cells and human umbilical vein endothelial cells

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价

[1]	吴肖锋, 陈丽薇, 张浩. 血清H-FABP、Ang-1在急性大血管闭塞性卒中静脉溶栓桥接支架取栓患者预后评估价值[J]. 广州医药, 2023, 54(8): 40-45.
[2]	李燕玲, 林国伟, 梁伟海, 刘晓俊. 制何首乌、巴戟天及其配伍对ox-LDL诱导的人脐静脉内皮细胞损伤的影响[J]. 广州医药, 2020, 51(5): 21-26.
[3]	矫元君, 尹耀新. miRNAs在肝细胞肝癌发展过程中的研究进展[J]. 广州医药, 2018, 49(2): 123-126.